414 related articles for article (PubMed ID: 37762318)
1. Circulating Sphingolipids in Insulin Resistance, Diabetes and Associated Complications.
Hammad SM; Lopes-Virella MF
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762318
[TBL] [Abstract][Full Text] [Related]
2. Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins.
Hammad SM; Hunt KJ; Baker NL; Klein RL; Lopes-Virella MF
J Clin Lipidol; 2022; 16(2):173-183. PubMed ID: 35148982
[TBL] [Abstract][Full Text] [Related]
3. Role of ceramides in the pathogenesis of diabetes mellitus and its complications.
Mandal N; Grambergs R; Mondal K; Basu SK; Tahia F; Dagogo-Jack S
J Diabetes Complications; 2021 Feb; 35(2):107734. PubMed ID: 33268241
[TBL] [Abstract][Full Text] [Related]
4. Sphingolipids as a Culprit of Mitochondrial Dysfunction in Insulin Resistance and Type 2 Diabetes.
Roszczyc-Owsiejczuk K; Zabielski P
Front Endocrinol (Lausanne); 2021; 12():635175. PubMed ID: 33815291
[TBL] [Abstract][Full Text] [Related]
5. Serum dihydroceramides correlate with insulin sensitivity in humans and decrease insulin sensitivity in vitro.
Zarini S; Brozinick JT; Zemski Berry KA; Garfield A; Perreault L; Kerege A; Bui HH; Sanders P; Siddall P; Kuo MS; Bergman BC
J Lipid Res; 2022 Oct; 63(10):100270. PubMed ID: 36030929
[TBL] [Abstract][Full Text] [Related]
6. Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet.
Brozinick JT; Hawkins E; Hoang Bui H; Kuo MS; Tan B; Kievit P; Grove K
Int J Obes (Lond); 2013 Aug; 37(8):1064-70. PubMed ID: 23207405
[TBL] [Abstract][Full Text] [Related]
7. Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?
Mah M; Febbraio M; Turpin-Nolan S
Front Endocrinol (Lausanne); 2021; 12():684448. PubMed ID: 34385976
[TBL] [Abstract][Full Text] [Related]
8. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.
Holland WL; Summers SA
Endocr Rev; 2008 Jun; 29(4):381-402. PubMed ID: 18451260
[TBL] [Abstract][Full Text] [Related]
9. Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study.
Lemaitre RN; Yu C; Hoofnagle A; Hari N; Jensen PN; Fretts AM; Umans JG; Howard BV; Sitlani CM; Siscovick DS; King IB; Sotoodehnia N; McKnight B
Diabetes; 2018 Aug; 67(8):1663-1672. PubMed ID: 29588286
[TBL] [Abstract][Full Text] [Related]
10. Differences in the Distribution of Ceramides and Sphingosine among Lipoprotein and Lipoprotein-Depleted Fractions in Patients with Type 2 Diabetes Mellitus.
Kurano M; Tsukamoto K; Sakai E; Yatomi Y
J Atheroscler Thromb; 2022 Dec; 29(12):1727-1758. PubMed ID: 35082227
[TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanisms of Sphingolipid Transport on Plasma Lipoproteins.
Iqbal J; Al Qarni A; Bakillah A
Adv Exp Med Biol; 2022; 1372():57-65. PubMed ID: 35503174
[TBL] [Abstract][Full Text] [Related]
12. The Role of Ceramides in Diabetes and Cardiovascular Disease Regulation of Ceramides by Adipokines.
Field BC; Gordillo R; Scherer PE
Front Endocrinol (Lausanne); 2020; 11():569250. PubMed ID: 33133017
[TBL] [Abstract][Full Text] [Related]
13. Sphingolipid Metabolism: New Insight into Ceramide-Induced Lipotoxicity in Muscle Cells.
Bandet CL; Tan-Chen S; Bourron O; Le Stunff H; Hajduch E
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678043
[TBL] [Abstract][Full Text] [Related]
14. Sphingolipids in obesity, type 2 diabetes, and metabolic disease.
Russo SB; Ross JS; Cowart LA
Handb Exp Pharmacol; 2013; (216):373-401. PubMed ID: 23563667
[TBL] [Abstract][Full Text] [Related]
15. Sphingolipid metabolism in brain insulin resistance and neurological diseases.
Mei M; Liu M; Mei Y; Zhao J; Li Y
Front Endocrinol (Lausanne); 2023; 14():1243132. PubMed ID: 37867511
[TBL] [Abstract][Full Text] [Related]
16. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans.
Bergman BC; Brozinick JT; Strauss A; Bacon S; Kerege A; Bui HH; Sanders P; Siddall P; Kuo MS; Perreault L
Am J Physiol Endocrinol Metab; 2015 Aug; 309(4):E398-408. PubMed ID: 26126684
[TBL] [Abstract][Full Text] [Related]
17. Rotten to the Cortex: Ceramide-Mediated Lipotoxicity in Diabetic Kidney Disease.
Nicholson RJ; Pezzolesi MG; Summers SA
Front Endocrinol (Lausanne); 2020; 11():622692. PubMed ID: 33584550
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic strategies for diabetes and complications: a role for sphingolipids?
Fox TE; Kester M
Adv Exp Med Biol; 2010; 688():206-16. PubMed ID: 20919656
[TBL] [Abstract][Full Text] [Related]
19. Sphingolipids and insulin resistance: the five Ws.
Summers SA
Curr Opin Lipidol; 2010 Apr; 21(2):128-35. PubMed ID: 20216312
[TBL] [Abstract][Full Text] [Related]
20. Circulating ceramides and sphingomyelins and the risk of incident cardiovascular disease among people with diabetes: the strong heart study.
Jensen PN; Fretts AM; Hoofnagle AN; McKnight B; Howard BV; Umans JG; Sitlani CM; Siscovick DS; King IB; Sotoodehnia N; Lemaitre RN
Cardiovasc Diabetol; 2022 Aug; 21(1):167. PubMed ID: 36042511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
